| lacosamide / Generic mfg. |
NCT00220415 / 2004-000290-58: A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg/Day and 400mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization |
|
|
| Completed | 3 | | Europe | SPM 927 | UCB Pharma | Partial Seizures With or Without Secondary Generalization | 01/06 | 01/06 | | |
NCT00136019: SPM 927 (400mg/Day and 600mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization |
|
|
| Completed | 3 | 400 | US | SPM 927 | UCB Pharma | Epilepsy | 08/06 | 08/06 | | |
NCT01710657 / 2014-003622-41: A Trial to Evaluate the Efficacy and Safety of Adjunctive Therapy With Lacosamide in Adults With Partial-Onset Seizures |
|
|
| Completed | 3 | 548 | Japan, RoW | Lacosamide 50 mg, Vimpat, Lacosamide 100 mg, Placebo | UCB Pharma SA, UCB Japan Co. Ltd. | Epilepsy, Partial Onset Seizures | 07/14 | 08/14 | | |
NCT02192814: Open-label Study to Evaluate the Safety and Tolerability of iv Lacosamide in Japanese Adults With Partial-onset Seizures |
|
|
| Completed | 3 | 9 | Japan | Lacosamide (200 mg/20 mL), Vimpat | UCB Japan Co. Ltd., Parexel | Epilepsy, Partial-onset Seizures | 10/14 | 12/14 | | |
| Completed | 2/3 | 160 | US | SPM 927 | UCB Pharma | Epilepsies, Partial | 05/06 | 05/06 | | |
